92 results
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
3:28pm
diagnosed AML patients. These preliminary data, presented at the 2021 American Society of Hematology Annual Meeting, showed the treatment was well
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
9:17am
patients. These preliminary data, presented at the 2021 American Society of Hematology Annual Meeting, showed the treatment was well-tolerated and there were
424B5
BPTH
Bio-Path Holdings Inc
4 Apr 24
Prospectus supplement for primary offering
4:33pm
. These preliminary data, presented at the 2021 American Society of Hematology Annual Meeting, showed the treatment was well-tolerated and there were no dose
424B5
BPTH
Bio-Path Holdings Inc
27 Mar 24
Prospectus supplement for primary offering
8:15am
diagnosed AML patients. These preliminary data, presented at the 2021 American Society of Hematology Annual Meeting, showed the treatment was well-tolerated
424B3
vdqtz61z2
7 Aug 23
Prospectus supplement
7:21am
424B4
nlklt
7 Aug 23
Prospectus supplement with pricing info
7:16am